We present the case of a 57-year-old woman with metastatic colorectal cancer being treated with Bevacizumab and FOLFOX, who came to the emergency department with haematemesis. Gastroscopy showed a duodenal ulcer without active bleeding. Subsequently, he suffered haemodynamic instability and an Angio-CT scan revealed an aortoenteric fistula, requiring urgent surgery. Bevacizumab can cause rare complications such as this, and early detection is crucial for effective treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17235/reed.2024.10773/2024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Palliative Care Following Aborted Cancer Surgery: Results of a Prospective Feasibility Trial.
Ann Surg Open
December 2024
Division of Palliative Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
Background: Although resection is generally necessary for curative-intent treatment of most solid organ cancers, surgery is occasionally aborted due to intraoperative findings. Following aborted cancer surgery, patients have unique care needs that specialized palliative care (PC) providers may be best equipped to manage. We hypothesized that early ambulatory PC referral following aborted cancer surgery would be feasible and acceptable.
View Article and Find Full Text PDFPredictors of Recurrence After Curative Surgery for Stage I Colon Cancer: Retrospective Cohort Analysis of the Italian Society of Surgical Oncology Colorectal Cancer Network Collaborative Group.
Ann Surg Open
December 2024
From the Chirurgia Generale ed Epatobiliare, Azienda Ospedaliera Universitaria Integrata di Verona, Università degli Studi di Verona, Verona, Italy.
Objective: The aim of this study is to provide solid evidence to update the management of stage I colon cancer (CC) after surgery.
Background: Given the low risk of recurrence of stage I CC, some international guidelines do not recommend intensive follow-up after surgery. However, data on the actual incidence, risk factors, and site of recurrences are scarce.
Nomograms Predicting Survival, Recurrence and Beneficiary Identification of Adjuvant Chemotherapy in Treatment-naïve Patients with Rectal Cancer who Underwent Upfront Curative Resection: A multi-institutional study.
Ann Surg Open
December 2024
Tokyo Medical and Dental University, The University of Tokyo, Tokyo, Japan.
Objective: To create and validate nomograms predicting overall survival and recurrence in treatment-naïve rectal cancer (RC) patients who underwent upfront surgery.
Background: Although multidisciplinary treatment is standard for locally advanced RC, understanding surgical efficacy is important for determining indications for perioperative adjuvant therapy.
Methods: RC patients who underwent upfront surgery at the Japanese Society for Cancer of the Colon and Rectum institutions were analyzed.
Circulating MiR-126 as a potential biomarker in Egyptian colorectal cancer patients: A case-control study.
Innate Immun
December 2024
Department of Clinical Pathology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Background: Globally, colorectal cancer (CRC) is among the most prevalent malignant tumors. It is characterized by unlimited proliferation, invasion, and metastasis. MicroRNA-126 (miR-126) has been shown in many studies to play a significant role in CRC, but data regarding its role in CRC Egyptian patients are limited.
View Article and Find Full Text PDFA Systematic Review and Meta-Analysis of the Efficacy and Safety of Regorafenib in the Treatment of Metastatic Colorectal Cancer.
J Gastrointest Cancer
December 2024
Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), Shenzhen, 518100, China.
Background And Objective: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Despite advances in treatment, metastatic colorectal cancer (mCRC) remains a significant challenge due to its heterogeneity and resistance to therapy. Regorafenib, a multikinase inhibitor, can inhibit tumor progression through multiple mechanisms, thereby improving patient prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!